Notícias
Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
Eli Lilly and Company (NYSE:LLY) shares gained about 1% in premarket trading Thursday after CVS Caremark announced it would add the company’s obesity treatment Zepbound to its preferred drug formulary. Lilly said the decision means all three of the largest pharmacy benefit managers in the United States will now provide coverage for the company’s full obesity medicine portfolio.
Eli Lilly and Company (NYSE:LLY) is included among the 10 Safe Stocks to Buy for the Long Term in 2026. On May 26, BofA raised the firm’s price recommendation for Eli Lilly and Company (NYSE:LLY) to $1,251 from $1,133. It reiterated a Buy rating on the shares. The firm said it expects Lilly’s future revenue […]
With a five-year EPS forecast of 28.38%, Eli Lilly and Company (NYSE:LLY) is among the 12 Best Future Stocks to Buy Right Now. On May 21, Eli Lilly and Company (NYSE:LLY) reported pivotal Phase 3 data for retatrutide that demonstrated weight loss of up to 26.1% at 80 weeks and more than 30% at 104 weeks in […]
We recently compiled a list of the 10 Most Widely Held Stocks by Individuals in 2026. Eli Lilly and Company (NYSE:LLY) is also one of the most widely held stock by individuals. TheFly reported on May 21 that Wolfe Research maintained an Outperform rating on LLY and kept its $1,350 price target unchanged. The firm […]
Small biotech firms "latch onto" AI more quickly than bigger firms, the head of Chinese tech giant Tencent's healthcare division said on Thursday, as more businesses embrace AI to improve efficiency. Pharmaceutical companies are also increasingly turning to AI to accelerate research and development, betting on new modeling tools and automated labs to improve efficiency and slash costs as well as drug development timelines. Drugmakers including Novo Nordisk and Eli Lilly have announced AI-related collaborations with technology firms.
Eli Lilly has outpaced the Nasdaq Composite over the past year, and analysts remain very confident in its longer-term trajectory.
The pharmacy benefit manager dropped Zepbound a year ago in favor of rival Wegovy — now both Lilly and Novo Nordisk drugs will be co-preferred options
The agreement includes Lilly’s new pill Foundayo and restores coverage for Zepbound, erasing what had been a commercial edge for rival Novo Nordisk.
May 28 () - CVS Health said on Thursday it will add Eli Lilly's weight-loss drug Zepbound back to some of its drug lists as an additional preferred option for insurance coverage. Caremark, CVS' pharmacy benefit management unit, had dropped Zepbound from coverage on July 1 last year, while continuing to reimburse for rival Novo Nordisk's Wegovy after negotiating a more favorable price from the Danish drugmaker.
Truist called Viking a “differentiated player” in the crowded obesity market, highlighting its flagship VK2735 candidate and dual oral-plus-injectable GLP-1 strategy.
Eli Lilly (LLY) stock has surged to new record highs of over $1,000 a share, cementing its position as one of the market's most dominant growth stories and the first pharmaceutical firm worth $1 trillion.
There is no reason to panic just yet.
Apogee Therapeutics revealed mixed results for its experimental eczema treatment Wednesday, and the stock dropped.
There’s a tech ETF that has been almost neck-and-neck with the S&P 500 in the past year and has built up a meaningful lead over the past five years. It’s the Vanguard’s Mega Cap Growth ETF (NYSEARCA:MGK). This ETF tracks the price of the CRSP US Mega Cap Growth Index, which in turn tracks companies ... Buy, Sell, or Hold Vanguard’s Mega Cap Growth ETF Right Now | MGK
Eli Lilly's fundamentals matter more than Trump's stock purchases.
Eli Lilly shares inch higher as the company announced three acquisitions for nearly $4 billion. Here’s why each of the three vaccine makers it’s buying is bullish for LLY stock.
LLY plans $3.83B in biotech buyouts to expand into vaccines and infectious diseases beyond obesity and diabetes.
Pharmaceutical companies have spent years targeting a common blood particle associated with heart-attack risks.
Hims & Hers Health shares have slumped in 2026 as the telehealth provider moves away from selling compounded GLP-1 medications.
NVO and AMGN square off as GLP-1 leadership, pipeline depth and diversification shape a compelling healthcare stock comparison.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
By Rishika Sadam and Sai Ishwarbharath B HYDERABAD/BENGALURU, May 27 (Reuters) - U.S. carrier American Airlines Group plans to double headcount at its India technology hub to about 800 by early next
As Lilly completes the pivotal program for its “triple-G” drug, Phase 1 data from Kailera partner Hengrui suggest their offering might spur greater weight loss.
Semiconductor powerhouse Micron Technology Inc. (NASDAQ:MU) vaulted on Tuesday, officially crossing the $1 trillion market capitalization milestone following a rally driven by demand for artificial intelligence (AI). Historic Market Cap Milestone The shares of the Idaho-based chipmaker closed 19.29% higher at $895.88, locking in a final market value of $1.010 trillion. According to data from CompaniesMarketCap, this monumental surge enabled Micron Technology to comfortably overtake legacy giants
BofA cut its HIMS price target to $25 from $28, while warning that the company’s 2026 outlook depends on a “significant” ramp-up in GLP-1 growth.
Eli Lilly's fair value estimate has shifted slightly from US$1,209.21 to US$1,211.03 per share, a small move that still reflects meaningful debate around what is already priced into the stock. Much of the recent analyst discussion links this updated target range to retatrutide Phase 3 data, with bulls highlighting GLP-1 leadership and bears questioning how much future obesity growth is already embedded. As you read on, you will see how these competing views shape the evolving narrative around...
Healthcare stocks were lower late Tuesday afternoon, with the NYSE Healthcare Index shedding 0.7% an